CA2368843C - Neurotrophic substituted pyrimidines - Google Patents
Neurotrophic substituted pyrimidines Download PDFInfo
- Publication number
- CA2368843C CA2368843C CA002368843A CA2368843A CA2368843C CA 2368843 C CA2368843 C CA 2368843C CA 002368843 A CA002368843 A CA 002368843A CA 2368843 A CA2368843 A CA 2368843A CA 2368843 C CA2368843 C CA 2368843C
- Authority
- CA
- Canada
- Prior art keywords
- pyrimidine
- amino
- chlorophenoxy
- trans
- 6alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000003230 pyrimidines Chemical class 0.000 title abstract description 6
- 230000000508 neurotrophic effect Effects 0.000 title description 7
- 230000000626 neurodegenerative effect Effects 0.000 claims abstract description 8
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 77
- -1 3-oxopiperidino Chemical group 0.000 claims description 56
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 49
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 27
- 150000001408 amides Chemical class 0.000 claims description 22
- 150000002148 esters Chemical class 0.000 claims description 22
- 239000012453 solvate Substances 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 125000001831 (C6-C10) heteroaryl group Chemical group 0.000 claims description 14
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 13
- 208000024827 Alzheimer disease Diseases 0.000 claims description 13
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 210000003169 central nervous system Anatomy 0.000 claims description 8
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 206010039966 Senile dementia Diseases 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 5
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 5
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000005505 thiomorpholino group Chemical group 0.000 claims description 4
- OOHHUMXTKNJKFW-UHFFFAOYSA-N 2-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclohexan-1-one Chemical compound C1CCCC(=O)C1NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 OOHHUMXTKNJKFW-UHFFFAOYSA-N 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- IDXKTTNFXPPXJY-UHFFFAOYSA-N pyrimidin-1-ium;chloride Chemical compound Cl.C1=CN=CN=C1 IDXKTTNFXPPXJY-UHFFFAOYSA-N 0.000 claims description 3
- UZMRXFMJIOWDAR-CABZTGNLSA-N (1s,2s)-2-[[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]methyl]cyclobutan-1-ol Chemical compound C([C@H]1[C@H](CC1)O)NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 UZMRXFMJIOWDAR-CABZTGNLSA-N 0.000 claims description 2
- FYLGFXDXZKSTJI-UHFFFAOYSA-N 1-[2-amino-5-[(2-chloro-4-ethylphenyl)methyl]pyrimidin-4-yl]piperidin-4-one Chemical compound ClC1=CC(CC)=CC=C1CC1=CN=C(N)N=C1N1CCC(=O)CC1 FYLGFXDXZKSTJI-UHFFFAOYSA-N 0.000 claims description 2
- QNTSGIHJDBCGDZ-UHFFFAOYSA-N 1-[2-amino-5-[(4-bromo-2-chlorophenyl)methyl]pyrimidin-4-yl]piperidin-4-one Chemical compound C1CC(=O)CCN1C1=NC(N)=NC=C1CC1=CC=C(Br)C=C1Cl QNTSGIHJDBCGDZ-UHFFFAOYSA-N 0.000 claims description 2
- JYSHIPCDPOXBKD-UHFFFAOYSA-N 1-[2-amino-5-[[2-chloro-4-(trifluoromethyl)phenyl]methyl]pyrimidin-4-yl]piperidin-3-one Chemical compound C1CCC(=O)CN1C1=NC(N)=NC=C1CC1=CC=C(C(F)(F)F)C=C1Cl JYSHIPCDPOXBKD-UHFFFAOYSA-N 0.000 claims description 2
- HQHHLBFGVUWFOG-UHFFFAOYSA-N 2-[[2-amino-5-(4-chloro-2-fluorophenoxy)pyrimidin-4-yl]amino]ethanol Chemical compound OCCNC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1F HQHHLBFGVUWFOG-UHFFFAOYSA-N 0.000 claims description 2
- KBNPUQQORGGSDW-UHFFFAOYSA-N 2-[[2-amino-5-(4-chloro-2-methylphenoxy)pyrimidin-4-yl]amino]ethanol Chemical compound CC1=CC(Cl)=CC=C1OC1=CN=C(N)N=C1NCCO KBNPUQQORGGSDW-UHFFFAOYSA-N 0.000 claims description 2
- IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 claims description 2
- IUQRNEUCHKJYDQ-UHFFFAOYSA-N 4-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclohexan-1-one Chemical compound C1CC(=O)CCC1NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 IUQRNEUCHKJYDQ-UHFFFAOYSA-N 0.000 claims description 2
- GRFUIFFKLNHNIC-UHFFFAOYSA-N 4-[[5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclohexan-1-one Chemical compound C1=CC(Cl)=CC=C1OC1=CN=CN=C1NC1CCC(=O)CC1 GRFUIFFKLNHNIC-UHFFFAOYSA-N 0.000 claims description 2
- UZCYYVJRMMNKRT-UHFFFAOYSA-N 5-(4-chlorophenoxy)-4-n-cyclohexylpyrimidine-2,4-diamine Chemical compound C1CCCCC1NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 UZCYYVJRMMNKRT-UHFFFAOYSA-N 0.000 claims description 2
- XNSDDHKPRDOTSP-SHTZXODSSA-N C1=CC(CC)=CC=C1OC1=CN=CN=C1N[C@@H]1CC[C@@H](O)CC1 Chemical compound C1=CC(CC)=CC=C1OC1=CN=CN=C1N[C@@H]1CC[C@@H](O)CC1 XNSDDHKPRDOTSP-SHTZXODSSA-N 0.000 claims description 2
- KDWGACNVLZXZNR-MQMHXKEQSA-N C1C[C@@H](CO)CC[C@@H]1NC1=NC=NC=C1OC1=CC=C(Cl)C=C1 Chemical compound C1C[C@@H](CO)CC[C@@H]1NC1=NC=NC=C1OC1=CC=C(Cl)C=C1 KDWGACNVLZXZNR-MQMHXKEQSA-N 0.000 claims description 2
- AXRMMTFWYVQFPL-JOCQHMNTSA-N C1C[C@@H](O)CC[C@@H]1NC1=NC=NC=C1OC1=CC=C(Cl)C=C1 Chemical compound C1C[C@@H](O)CC[C@@H]1NC1=NC=NC=C1OC1=CC=C(Cl)C=C1 AXRMMTFWYVQFPL-JOCQHMNTSA-N 0.000 claims description 2
- KGPFXCLEMKEENC-HAQNSBGRSA-N C1C[C@@H](O)CC[C@@H]1NC1=NC=NC=C1OC1=CC=C(Cl)C=C1F Chemical compound C1C[C@@H](O)CC[C@@H]1NC1=NC=NC=C1OC1=CC=C(Cl)C=C1F KGPFXCLEMKEENC-HAQNSBGRSA-N 0.000 claims description 2
- PUVKKJGFDNSRFV-AULYBMBSSA-N N([C@@H]1CC[C@@H](CO)CC1)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 Chemical compound N([C@@H]1CC[C@@H](CO)CC1)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 PUVKKJGFDNSRFV-AULYBMBSSA-N 0.000 claims description 2
- AWYGONCSOZSLRM-XYPYZODXSA-N N([C@@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1Cl Chemical compound N([C@@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1Cl AWYGONCSOZSLRM-XYPYZODXSA-N 0.000 claims description 2
- DQTSGKSDZKDJCS-XYPYZODXSA-N N([C@@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1F Chemical compound N([C@@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1F DQTSGKSDZKDJCS-XYPYZODXSA-N 0.000 claims description 2
- ZNVWVEWNCWSELJ-UHFFFAOYSA-N [1-[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]pyrrolidin-2-yl]methanol Chemical compound C1CCC(CO)N1C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 ZNVWVEWNCWSELJ-UHFFFAOYSA-N 0.000 claims description 2
- PTRZEOYINPNTSI-UHFFFAOYSA-N [4-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]phenyl] acetate Chemical compound C1=CC(OC(=O)C)=CC=C1NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 PTRZEOYINPNTSI-UHFFFAOYSA-N 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000003963 dichloro group Chemical group Cl* 0.000 claims description 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims description 2
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- RMNGMDPYIVUTFS-UHFFFAOYSA-N n-[2-amino-5-(4-bromophenoxy)pyrimidin-4-yl]-n-phenylhydroxylamine Chemical compound C=1C=CC=CC=1N(O)C1=NC(N)=NC=C1OC1=CC=C(Br)C=C1 RMNGMDPYIVUTFS-UHFFFAOYSA-N 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 102200001405 rs377584435 Human genes 0.000 claims description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 2
- 125000000464 thioxo group Chemical group S=* 0.000 claims description 2
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 claims description 2
- WDRVZKJGSJDXON-CHWSQXEVSA-N (1r,2r)-2-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclohexan-1-ol Chemical compound N([C@H]1[C@@H](CCCC1)O)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 WDRVZKJGSJDXON-CHWSQXEVSA-N 0.000 claims 1
- XPMQRFWGMBVRDV-VXGBXAGGSA-N (1r,2r)-2-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclopentan-1-ol Chemical compound N([C@H]1[C@@H](CCC1)O)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 XPMQRFWGMBVRDV-VXGBXAGGSA-N 0.000 claims 1
- IIQRPFMJYHBHFT-CHWSQXEVSA-N (1r,2r)-2-[[5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclopentan-1-ol Chemical compound O[C@@H]1CCC[C@H]1NC1=NC=NC=C1OC1=CC=C(Cl)C=C1 IIQRPFMJYHBHFT-CHWSQXEVSA-N 0.000 claims 1
- UZMRXFMJIOWDAR-JOYOIKCWSA-N (1r,2s)-2-[[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]methyl]cyclobutan-1-ol Chemical compound C([C@H]1[C@@H](CC1)O)NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 UZMRXFMJIOWDAR-JOYOIKCWSA-N 0.000 claims 1
- RVKBVGVAFLHOPI-SMDDNHRTSA-N (1r,2s)-2-[[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]methyl]cyclohexan-1-ol Chemical compound C([C@H]1[C@@H](CCCC1)O)NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 RVKBVGVAFLHOPI-SMDDNHRTSA-N 0.000 claims 1
- YMLAIIULOFNEBL-GXFFZTMASA-N (1r,2s)-2-[[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]methyl]cyclopentan-1-ol Chemical compound C([C@H]1[C@@H](CCC1)O)NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 YMLAIIULOFNEBL-GXFFZTMASA-N 0.000 claims 1
- DQWTZTCKHNOTQM-NWDGAFQWSA-N (1r,3s)-3-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclohexan-1-ol Chemical compound N([C@@H]1C[C@H](O)CCC1)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 DQWTZTCKHNOTQM-NWDGAFQWSA-N 0.000 claims 1
- VMHKCSIZCDEGEJ-WDEREUQCSA-N (1r,3s)-3-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclopentan-1-ol Chemical compound N([C@@H]1C[C@H](O)CC1)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 VMHKCSIZCDEGEJ-WDEREUQCSA-N 0.000 claims 1
- NHDLPPJQUWJAEU-QWHCGFSZSA-N (1r,3s)-3-[[5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclohexan-1-ol Chemical compound C1[C@H](O)CCC[C@@H]1NC1=NC=NC=C1OC1=CC=C(Cl)C=C1 NHDLPPJQUWJAEU-QWHCGFSZSA-N 0.000 claims 1
- SPNNAWYJVKRRAK-WCQYABFASA-N (1r,3s)-3-[[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]methyl]cyclohexan-1-ol Chemical compound C([C@@H]1C[C@H](O)CCC1)NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 SPNNAWYJVKRRAK-WCQYABFASA-N 0.000 claims 1
- OWJCJDQFSBGPRX-CMPLNLGQSA-N (1r,3s)-3-[[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]methyl]cyclopentan-1-ol Chemical compound C([C@@H]1C[C@H](O)CC1)NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 OWJCJDQFSBGPRX-CMPLNLGQSA-N 0.000 claims 1
- WDRVZKJGSJDXON-OLZOCXBDSA-N (1s,2r)-2-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclohexan-1-ol Chemical compound N([C@H]1[C@H](CCCC1)O)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 WDRVZKJGSJDXON-OLZOCXBDSA-N 0.000 claims 1
- XPMQRFWGMBVRDV-NEPJUHHUSA-N (1s,2r)-2-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclopentan-1-ol Chemical compound N([C@H]1[C@H](CCC1)O)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 XPMQRFWGMBVRDV-NEPJUHHUSA-N 0.000 claims 1
- RVKBVGVAFLHOPI-FZMZJTMJSA-N (1s,2s)-2-[[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]methyl]cyclohexan-1-ol Chemical compound C([C@H]1[C@H](CCCC1)O)NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 RVKBVGVAFLHOPI-FZMZJTMJSA-N 0.000 claims 1
- YMLAIIULOFNEBL-GWCFXTLKSA-N (1s,2s)-2-[[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]methyl]cyclopentan-1-ol Chemical compound C([C@H]1[C@H](CCC1)O)NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 YMLAIIULOFNEBL-GWCFXTLKSA-N 0.000 claims 1
- DQWTZTCKHNOTQM-RYUDHWBXSA-N (1s,3s)-3-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclohexan-1-ol Chemical compound N([C@@H]1C[C@@H](O)CCC1)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 DQWTZTCKHNOTQM-RYUDHWBXSA-N 0.000 claims 1
- VMHKCSIZCDEGEJ-QWRGUYRKSA-N (1s,3s)-3-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclopentan-1-ol Chemical compound N([C@@H]1C[C@@H](O)CC1)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 VMHKCSIZCDEGEJ-QWRGUYRKSA-N 0.000 claims 1
- WCGXTJTYWBFRCH-RYUDHWBXSA-N (1s,3s)-3-[[5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclopentan-1-ol Chemical compound C1[C@@H](O)CC[C@@H]1NC1=NC=NC=C1OC1=CC=C(Cl)C=C1 WCGXTJTYWBFRCH-RYUDHWBXSA-N 0.000 claims 1
- SPNNAWYJVKRRAK-AAEUAGOBSA-N (1s,3s)-3-[[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]methyl]cyclohexan-1-ol Chemical compound C([C@@H]1C[C@@H](O)CCC1)NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 SPNNAWYJVKRRAK-AAEUAGOBSA-N 0.000 claims 1
- OWJCJDQFSBGPRX-JQWIXIFHSA-N (1s,3s)-3-[[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]methyl]cyclopentan-1-ol Chemical compound C([C@@H]1C[C@@H](O)CC1)NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 OWJCJDQFSBGPRX-JQWIXIFHSA-N 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- HMVXMQDEQZMYTM-UHFFFAOYSA-N 1-[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]pyrrolidin-3-ol Chemical compound C1CC(O)CN1C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 HMVXMQDEQZMYTM-UHFFFAOYSA-N 0.000 claims 1
- DLQKRKXAPMSNIU-UHFFFAOYSA-N 1-[2-amino-5-[(2,4-dichlorophenyl)methyl]pyrimidin-4-yl]piperidin-3-one Chemical compound C1CCC(=O)CN1C1=NC(N)=NC=C1CC1=CC=C(Cl)C=C1Cl DLQKRKXAPMSNIU-UHFFFAOYSA-N 0.000 claims 1
- PSDOJMKHHBVUKY-UHFFFAOYSA-N 1-[2-amino-5-[(2,4-dichlorophenyl)methyl]pyrimidin-4-yl]piperidin-4-one Chemical compound C1CC(=O)CCN1C1=NC(N)=NC=C1CC1=CC=C(Cl)C=C1Cl PSDOJMKHHBVUKY-UHFFFAOYSA-N 0.000 claims 1
- MFLSOPKYZJZSBT-UHFFFAOYSA-N 1-[2-amino-5-[(2-chloro-4-ethylphenyl)methyl]pyrimidin-4-yl]piperidin-3-one Chemical compound ClC1=CC(CC)=CC=C1CC1=CN=C(N)N=C1N1CC(=O)CCC1 MFLSOPKYZJZSBT-UHFFFAOYSA-N 0.000 claims 1
- PQCHKBRHYRPMQA-UHFFFAOYSA-N 1-[2-amino-5-[(2-chloro-4-methylphenyl)methyl]pyrimidin-4-yl]piperidin-3-one Chemical compound ClC1=CC(C)=CC=C1CC1=CN=C(N)N=C1N1CC(=O)CCC1 PQCHKBRHYRPMQA-UHFFFAOYSA-N 0.000 claims 1
- MNDXSQASUHYHSJ-UHFFFAOYSA-N 1-[2-amino-5-[(2-chloro-4-methylphenyl)methyl]pyrimidin-4-yl]piperidin-4-one Chemical compound ClC1=CC(C)=CC=C1CC1=CN=C(N)N=C1N1CCC(=O)CC1 MNDXSQASUHYHSJ-UHFFFAOYSA-N 0.000 claims 1
- BBBPAIHLXDVRDM-UHFFFAOYSA-N 1-[2-amino-5-[(4-bromo-2-chlorophenyl)methyl]pyrimidin-4-yl]piperidin-3-one Chemical compound C1CCC(=O)CN1C1=NC(N)=NC=C1CC1=CC=C(Br)C=C1Cl BBBPAIHLXDVRDM-UHFFFAOYSA-N 0.000 claims 1
- DHIZPSVXNNFCRI-UHFFFAOYSA-N 1-[2-amino-5-[(4-bromophenyl)methyl]pyrimidin-4-yl]piperidin-3-one Chemical compound C1CCC(=O)CN1C1=NC(N)=NC=C1CC1=CC=C(Br)C=C1 DHIZPSVXNNFCRI-UHFFFAOYSA-N 0.000 claims 1
- XTGCAFJJANFPJK-UHFFFAOYSA-N 1-[2-amino-5-[(4-bromophenyl)methyl]pyrimidin-4-yl]piperidin-4-one Chemical compound C1CC(=O)CCN1C1=NC(N)=NC=C1CC1=CC=C(Br)C=C1 XTGCAFJJANFPJK-UHFFFAOYSA-N 0.000 claims 1
- ISYITNRSSWFOQN-UHFFFAOYSA-N 1-[2-amino-5-[(4-chlorophenyl)methyl]pyrimidin-4-yl]piperidin-3-one Chemical compound C1CCC(=O)CN1C1=NC(N)=NC=C1CC1=CC=C(Cl)C=C1 ISYITNRSSWFOQN-UHFFFAOYSA-N 0.000 claims 1
- URNSBDYTIUKUCV-UHFFFAOYSA-N 1-[2-amino-5-[(4-chlorophenyl)methyl]pyrimidin-4-yl]piperidin-4-one Chemical compound C1CC(=O)CCN1C1=NC(N)=NC=C1CC1=CC=C(Cl)C=C1 URNSBDYTIUKUCV-UHFFFAOYSA-N 0.000 claims 1
- UUSDFVXOGINRFP-UHFFFAOYSA-N 1-[2-amino-5-[(4-ethylphenyl)methyl]pyrimidin-4-yl]piperidin-3-one Chemical compound C1=CC(CC)=CC=C1CC1=CN=C(N)N=C1N1CC(=O)CCC1 UUSDFVXOGINRFP-UHFFFAOYSA-N 0.000 claims 1
- XWWPKPYRRPVEFR-UHFFFAOYSA-N 1-[2-amino-5-[(4-ethylphenyl)methyl]pyrimidin-4-yl]piperidin-4-one Chemical compound C1=CC(CC)=CC=C1CC1=CN=C(N)N=C1N1CCC(=O)CC1 XWWPKPYRRPVEFR-UHFFFAOYSA-N 0.000 claims 1
- OGYRCYLGGBLDNE-UHFFFAOYSA-N 1-[2-amino-5-[(4-methylphenyl)methyl]pyrimidin-4-yl]piperidin-3-one Chemical compound C1=CC(C)=CC=C1CC1=CN=C(N)N=C1N1CC(=O)CCC1 OGYRCYLGGBLDNE-UHFFFAOYSA-N 0.000 claims 1
- MGDXSHBMPWDXNP-UHFFFAOYSA-N 1-[2-amino-5-[(4-methylphenyl)methyl]pyrimidin-4-yl]piperidin-4-one Chemical compound C1=CC(C)=CC=C1CC1=CN=C(N)N=C1N1CCC(=O)CC1 MGDXSHBMPWDXNP-UHFFFAOYSA-N 0.000 claims 1
- HVSWPWMMANEHEU-UHFFFAOYSA-N 1-[2-amino-5-[[2-chloro-4-(trifluoromethyl)phenyl]methyl]pyrimidin-4-yl]piperidin-4-one Chemical compound C1CC(=O)CCN1C1=NC(N)=NC=C1CC1=CC=C(C(F)(F)F)C=C1Cl HVSWPWMMANEHEU-UHFFFAOYSA-N 0.000 claims 1
- KUTSDGMIBJHPJY-UHFFFAOYSA-N 1-[2-amino-5-[[3-(trifluoromethyl)phenyl]methyl]pyrimidin-4-yl]piperidin-4-one Chemical compound C1CC(=O)CCN1C1=NC(N)=NC=C1CC1=CC=CC(C(F)(F)F)=C1 KUTSDGMIBJHPJY-UHFFFAOYSA-N 0.000 claims 1
- QMWNZBIJHRYITL-UHFFFAOYSA-N 1-[2-amino-5-[[4-(trifluoromethyl)phenyl]methyl]pyrimidin-4-yl]piperidin-4-one Chemical compound C1CC(=O)CCN1C1=NC(N)=NC=C1CC1=CC=C(C(F)(F)F)C=C1 QMWNZBIJHRYITL-UHFFFAOYSA-N 0.000 claims 1
- OOTYZGKEQOZJFC-UHFFFAOYSA-N 1-[[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]methyl]cyclobutan-1-ol Chemical compound C1CCC1(O)CNC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 OOTYZGKEQOZJFC-UHFFFAOYSA-N 0.000 claims 1
- USWCOVSSFKSWAV-UHFFFAOYSA-N 1-[[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]methyl]cyclohexan-1-ol Chemical compound C1CCCCC1(O)CNC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 USWCOVSSFKSWAV-UHFFFAOYSA-N 0.000 claims 1
- DSIGYQXGLRBGIR-UHFFFAOYSA-N 1-[[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]methyl]cyclopentan-1-ol Chemical compound C1CCCC1(O)CNC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 DSIGYQXGLRBGIR-UHFFFAOYSA-N 0.000 claims 1
- ZUHNCYXOCMYTBJ-UHFFFAOYSA-N 1-[[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]methyl]cyclopropan-1-ol Chemical compound C1CC1(O)CNC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 ZUHNCYXOCMYTBJ-UHFFFAOYSA-N 0.000 claims 1
- VMKUHZBJUWCWOR-IUODEOHRSA-N 2-[(1r,2r)-2-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclohexyl]ethanol Chemical compound N([C@H]1[C@H](CCCC1)CCO)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 VMKUHZBJUWCWOR-IUODEOHRSA-N 0.000 claims 1
- YLTHCBGIXGRYNM-BXUZGUMPSA-N 2-[(1r,2r)-2-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclopentyl]ethanol Chemical compound N([C@H]1[C@H](CCC1)CCO)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 YLTHCBGIXGRYNM-BXUZGUMPSA-N 0.000 claims 1
- GSANIAKTEQGRHY-JSGCOSHPSA-N 2-[(1r,3s)-3-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclohexyl]ethanol Chemical compound N([C@@H]1C[C@H](CCO)CCC1)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 GSANIAKTEQGRHY-JSGCOSHPSA-N 0.000 claims 1
- RLBDHOOKZSUTDK-AAEUAGOBSA-N 2-[(1r,3s)-3-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclopentyl]ethanol Chemical compound N([C@@H]1C[C@H](CCO)CC1)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 RLBDHOOKZSUTDK-AAEUAGOBSA-N 0.000 claims 1
- YLTHCBGIXGRYNM-SMDDNHRTSA-N 2-[(1s,2r)-2-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclopentyl]ethanol Chemical compound N([C@H]1[C@@H](CCC1)CCO)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 YLTHCBGIXGRYNM-SMDDNHRTSA-N 0.000 claims 1
- GSANIAKTEQGRHY-OCCSQVGLSA-N 2-[(1s,3s)-3-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclohexyl]ethanol Chemical compound N([C@@H]1C[C@@H](CCO)CCC1)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 GSANIAKTEQGRHY-OCCSQVGLSA-N 0.000 claims 1
- RLBDHOOKZSUTDK-YPMHNXCESA-N 2-[(1s,3s)-3-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclopentyl]ethanol Chemical compound N([C@@H]1C[C@@H](CCO)CC1)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 RLBDHOOKZSUTDK-YPMHNXCESA-N 0.000 claims 1
- ACOFJKVGAQINAZ-UHFFFAOYSA-N 2-[1-[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]pyrrolidin-2-yl]ethanol Chemical compound C1CCC(CCO)N1C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 ACOFJKVGAQINAZ-UHFFFAOYSA-N 0.000 claims 1
- DZWPIXQTZZRCTC-UHFFFAOYSA-N 2-[1-[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]pyrrolidin-3-yl]ethanol Chemical compound C1CC(CCO)CN1C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 DZWPIXQTZZRCTC-UHFFFAOYSA-N 0.000 claims 1
- XLXCHQWJDGNEGK-UHFFFAOYSA-N 2-[[2-amino-5-(2,4-dichlorophenoxy)pyrimidin-4-yl]amino]cyclohexan-1-one Chemical compound C1CCCC(=O)C1NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1Cl XLXCHQWJDGNEGK-UHFFFAOYSA-N 0.000 claims 1
- VAGKCYDEYMSPKA-UHFFFAOYSA-N 2-[[2-amino-5-(2,4-dichlorophenoxy)pyrimidin-4-yl]amino]ethanol Chemical compound OCCNC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1Cl VAGKCYDEYMSPKA-UHFFFAOYSA-N 0.000 claims 1
- ZFTUZEYUNQVENH-UHFFFAOYSA-N 2-[[2-amino-5-(2-chloro-4-fluorophenoxy)pyrimidin-4-yl]amino]ethanol Chemical compound OCCNC1=NC(N)=NC=C1OC1=CC=C(F)C=C1Cl ZFTUZEYUNQVENH-UHFFFAOYSA-N 0.000 claims 1
- WGVCWHKAYFETGK-UHFFFAOYSA-N 2-[[2-amino-5-(4-bromophenoxy)pyrimidin-4-yl]amino]cyclohexan-1-one Chemical compound C1CCCC(=O)C1NC1=NC(N)=NC=C1OC1=CC=C(Br)C=C1 WGVCWHKAYFETGK-UHFFFAOYSA-N 0.000 claims 1
- HIEHNPTXCIQJAK-UHFFFAOYSA-N 2-[[2-amino-5-(4-bromophenoxy)pyrimidin-4-yl]amino]ethanol Chemical compound OCCNC1=NC(N)=NC=C1OC1=CC=C(Br)C=C1 HIEHNPTXCIQJAK-UHFFFAOYSA-N 0.000 claims 1
- HIXIKQQUYWMVPC-UHFFFAOYSA-N 2-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]-(2-hydroxyethyl)amino]ethanol Chemical compound OCCN(CCO)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 HIXIKQQUYWMVPC-UHFFFAOYSA-N 0.000 claims 1
- AGYZQOBNGYVHDI-UHFFFAOYSA-N 2-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]-(hydroxymethyl)amino]ethanol Chemical compound NC1=NC=C(C(=N1)N(CCO)CO)OC1=CC=C(C=C1)Cl AGYZQOBNGYVHDI-UHFFFAOYSA-N 0.000 claims 1
- NRMPZRQPHTUMTL-UHFFFAOYSA-N 2-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 NRMPZRQPHTUMTL-UHFFFAOYSA-N 0.000 claims 1
- IQVXQPDVICCRMK-UHFFFAOYSA-N 2-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]-2-methylpropan-1-ol Chemical compound OCC(C)(C)NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 IQVXQPDVICCRMK-UHFFFAOYSA-N 0.000 claims 1
- AMDOJUGAWPFWQB-UHFFFAOYSA-N 2-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]butane-1,4-diol Chemical compound OCCC(CO)NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 AMDOJUGAWPFWQB-UHFFFAOYSA-N 0.000 claims 1
- VIHOBYXQIUOIHP-UHFFFAOYSA-N 2-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclopentan-1-one Chemical compound C1CCC(=O)C1NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 VIHOBYXQIUOIHP-UHFFFAOYSA-N 0.000 claims 1
- UDDJXYHPSUBHLP-UHFFFAOYSA-N 2-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]ethanol Chemical compound OCCNC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 UDDJXYHPSUBHLP-UHFFFAOYSA-N 0.000 claims 1
- SZANPKTXWJIKRI-UHFFFAOYSA-N 2-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]oxyethanol Chemical compound OCCONC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 SZANPKTXWJIKRI-UHFFFAOYSA-N 0.000 claims 1
- AWUVVMYYNWXAKH-UHFFFAOYSA-N 2-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]propan-1-ol Chemical compound OCC(C)NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 AWUVVMYYNWXAKH-UHFFFAOYSA-N 0.000 claims 1
- RENAGPBLGOCXCR-UHFFFAOYSA-N 2-[[2-amino-5-(4-ethylphenoxy)pyrimidin-4-yl]amino]cyclohexan-1-one Chemical compound C1=CC(CC)=CC=C1OC1=CN=C(N)N=C1NC1C(=O)CCCC1 RENAGPBLGOCXCR-UHFFFAOYSA-N 0.000 claims 1
- QGSALYQGLVDJEM-UHFFFAOYSA-N 2-[[2-amino-5-(4-ethylphenoxy)pyrimidin-4-yl]amino]ethanol Chemical compound C1=CC(CC)=CC=C1OC1=CN=C(N)N=C1NCCO QGSALYQGLVDJEM-UHFFFAOYSA-N 0.000 claims 1
- RCNLSQVSQMWTSH-UHFFFAOYSA-N 2-[[2-amino-5-(4-methylphenoxy)pyrimidin-4-yl]amino]cyclohexan-1-one Chemical compound C1=CC(C)=CC=C1OC1=CN=C(N)N=C1NC1C(=O)CCCC1 RCNLSQVSQMWTSH-UHFFFAOYSA-N 0.000 claims 1
- BAZDVHPPFJTDHB-UHFFFAOYSA-N 2-[[2-amino-5-(4-methylphenoxy)pyrimidin-4-yl]amino]ethanol Chemical compound C1=CC(C)=CC=C1OC1=CN=C(N)N=C1NCCO BAZDVHPPFJTDHB-UHFFFAOYSA-N 0.000 claims 1
- VIFIWZAWDCDBDU-UHFFFAOYSA-N 2-[[5-(4-chlorophenoxy)pyrimidin-4-yl]amino]ethanol Chemical compound OCCNC1=NC=NC=C1OC1=CC=C(Cl)C=C1 VIFIWZAWDCDBDU-UHFFFAOYSA-N 0.000 claims 1
- UGARQXKOHMROFE-UHFFFAOYSA-N 3-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]-(3-hydroxypropyl)amino]propan-1-ol Chemical compound OCCCN(CCCO)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 UGARQXKOHMROFE-UHFFFAOYSA-N 0.000 claims 1
- PEHOUJSYUZOSLD-UHFFFAOYSA-N 3-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclohexan-1-one Chemical compound C1CCC(=O)CC1NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 PEHOUJSYUZOSLD-UHFFFAOYSA-N 0.000 claims 1
- LHWWMGODLYXRRV-UHFFFAOYSA-N 3-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclopentan-1-one Chemical compound C1CC(=O)CC1NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 LHWWMGODLYXRRV-UHFFFAOYSA-N 0.000 claims 1
- NGMFTJGNZXJWMO-UHFFFAOYSA-N 3-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]propan-1-ol Chemical compound OCCCNC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 NGMFTJGNZXJWMO-UHFFFAOYSA-N 0.000 claims 1
- LNFXCKDQZXDJHJ-UHFFFAOYSA-N 3-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]propane-1,2-diol Chemical compound OCC(O)CNC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 LNFXCKDQZXDJHJ-UHFFFAOYSA-N 0.000 claims 1
- OETOQMORKGXZAN-UHFFFAOYSA-N 4-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]-2-chlorophenol Chemical compound C=1C=C(O)C(Cl)=CC=1NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 OETOQMORKGXZAN-UHFFFAOYSA-N 0.000 claims 1
- REFUFYATTVIZSM-UHFFFAOYSA-N 4-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]-3-chlorophenol Chemical compound C=1C=C(O)C=C(Cl)C=1NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 REFUFYATTVIZSM-UHFFFAOYSA-N 0.000 claims 1
- YXAONWAIFKGGRJ-UHFFFAOYSA-N 4-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]-3-methylphenol Chemical compound CC1=CC(O)=CC=C1NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 YXAONWAIFKGGRJ-UHFFFAOYSA-N 0.000 claims 1
- XUPUFACANDPWKE-UHFFFAOYSA-N 4-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]butan-1-ol Chemical compound OCCCCNC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 XUPUFACANDPWKE-UHFFFAOYSA-N 0.000 claims 1
- FLCWCRBOQUPBSP-UHFFFAOYSA-N 4-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]butane-1,2-diol Chemical compound OCC(O)CCNC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 FLCWCRBOQUPBSP-UHFFFAOYSA-N 0.000 claims 1
- UFSPXXMLIZPAOR-UHFFFAOYSA-N 4-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]phenol Chemical compound C=1C=C(O)C=CC=1NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 UFSPXXMLIZPAOR-UHFFFAOYSA-N 0.000 claims 1
- NTIDPDTXXPNLPE-UHFFFAOYSA-N 5-(4-chlorophenoxy)-4-n-methoxypyrimidine-2,4-diamine Chemical compound CONC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 NTIDPDTXXPNLPE-UHFFFAOYSA-N 0.000 claims 1
- VBZKDFXIJPJHRP-UHFFFAOYSA-N 5-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]pentan-1-ol Chemical compound OCCCCCNC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 VBZKDFXIJPJHRP-UHFFFAOYSA-N 0.000 claims 1
- YMBAHRPIFUFGFY-UHFFFAOYSA-N 6-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]hexan-1-ol Chemical compound OCCCCCCNC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 YMBAHRPIFUFGFY-UHFFFAOYSA-N 0.000 claims 1
- CSRSPCGOJWJCQM-AULYBMBSSA-N C([C@@H]1CC[C@@H](O)CC1)NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 Chemical compound C([C@@H]1CC[C@@H](O)CC1)NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 CSRSPCGOJWJCQM-AULYBMBSSA-N 0.000 claims 1
- VFHOJTLYPYMYNU-XYPYZODXSA-N C([C@@H]1C[C@@H](CO)C1)NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 Chemical compound C([C@@H]1C[C@@H](CO)C1)NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 VFHOJTLYPYMYNU-XYPYZODXSA-N 0.000 claims 1
- FXGQHZPLBDFIHK-HOMQSWHASA-N C([C@@H]1C[C@@H](O)C1)NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 Chemical compound C([C@@H]1C[C@@H](O)C1)NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 FXGQHZPLBDFIHK-HOMQSWHASA-N 0.000 claims 1
- CSRSPCGOJWJCQM-BJHJDKERSA-N C([C@H]1CC[C@@H](O)CC1)NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 Chemical compound C([C@H]1CC[C@@H](O)CC1)NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 CSRSPCGOJWJCQM-BJHJDKERSA-N 0.000 claims 1
- VFHOJTLYPYMYNU-PHIMTYICSA-N C([C@H]1C[C@@H](CO)C1)NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 Chemical compound C([C@H]1C[C@@H](CO)C1)NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 VFHOJTLYPYMYNU-PHIMTYICSA-N 0.000 claims 1
- FXGQHZPLBDFIHK-JGZJWPJOSA-N C([C@H]1C[C@@H](O)C1)NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 Chemical compound C([C@H]1C[C@@H](O)C1)NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 FXGQHZPLBDFIHK-JGZJWPJOSA-N 0.000 claims 1
- SCCNPIIXGBJQAJ-SHTZXODSSA-N C1=CC(C(C)C)=CC=C1OC1=CN=C(N)N=C1N[C@@H]1CC[C@@H](O)CC1 Chemical compound C1=CC(C(C)C)=CC=C1OC1=CN=C(N)N=C1N[C@@H]1CC[C@@H](O)CC1 SCCNPIIXGBJQAJ-SHTZXODSSA-N 0.000 claims 1
- UATMTCDFYMQVSR-WKILWMFISA-N C1=CC(C)=CC=C1CC1=CN=C(N)N=C1N[C@@H]1CC[C@@H](O)CC1 Chemical compound C1=CC(C)=CC=C1CC1=CN=C(N)N=C1N[C@@H]1CC[C@@H](O)CC1 UATMTCDFYMQVSR-WKILWMFISA-N 0.000 claims 1
- PICBEVDBSSCZSF-JOCQHMNTSA-N C1=CC(C)=CC=C1OC1=CN=C(N)N=C1N[C@@H]1CC[C@@H](O)CC1 Chemical compound C1=CC(C)=CC=C1OC1=CN=C(N)N=C1N[C@@H]1CC[C@@H](O)CC1 PICBEVDBSSCZSF-JOCQHMNTSA-N 0.000 claims 1
- OSLUMCKEOSLYKZ-WKILWMFISA-N C1=CC(CCCC)=CC=C1OC1=CN=C(N)N=C1N[C@@H]1CC[C@@H](O)CC1 Chemical compound C1=CC(CCCC)=CC=C1OC1=CN=C(N)N=C1N[C@@H]1CC[C@@H](O)CC1 OSLUMCKEOSLYKZ-WKILWMFISA-N 0.000 claims 1
- QWMCWBDBXKNJCV-HAQNSBGRSA-N C1=CC(OC)=CC=C1OC1=CN=C(N)N=C1N[C@@H]1CC[C@@H](O)CC1 Chemical compound C1=CC(OC)=CC=C1OC1=CN=C(N)N=C1N[C@@H]1CC[C@@H](O)CC1 QWMCWBDBXKNJCV-HAQNSBGRSA-N 0.000 claims 1
- KFBKRZUSACROEN-JOCQHMNTSA-N C1C[C@@H](O)CC[C@@H]1NC1=NC=NC=C1OC1=CC=C(C(F)(F)F)C=C1 Chemical compound C1C[C@@H](O)CC[C@@H]1NC1=NC=NC=C1OC1=CC=C(C(F)(F)F)C=C1 KFBKRZUSACROEN-JOCQHMNTSA-N 0.000 claims 1
- YMRSBNASEGMRIF-HAQNSBGRSA-N C1C[C@@H](O)CC[C@@H]1NC1=NC=NC=C1OC1=CC=C(Cl)C=C1Cl Chemical compound C1C[C@@H](O)CC[C@@H]1NC1=NC=NC=C1OC1=CC=C(Cl)C=C1Cl YMRSBNASEGMRIF-HAQNSBGRSA-N 0.000 claims 1
- AXRMMTFWYVQFPL-BETUJISGSA-N C1C[C@@H](O)CC[C@H]1NC1=NC=NC=C1OC1=CC=C(Cl)C=C1 Chemical compound C1C[C@@H](O)CC[C@H]1NC1=NC=NC=C1OC1=CC=C(Cl)C=C1 AXRMMTFWYVQFPL-BETUJISGSA-N 0.000 claims 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
- ZXJPSZFTSWBJRR-XYPYZODXSA-N C=1C=C(Cl)C=CC=1OC=1C(C(F)(F)F)=NC(N)=NC=1N[C@H]1CC[C@H](O)CC1 Chemical compound C=1C=C(Cl)C=CC=1OC=1C(C(F)(F)F)=NC(N)=NC=1N[C@H]1CC[C@H](O)CC1 ZXJPSZFTSWBJRR-XYPYZODXSA-N 0.000 claims 1
- MSLVTEIEQSZWOQ-IBOPQAGSSA-N C=1N=C(N)N=C(N[C@@H]2CC[C@@H](O)CC2)C=1C(C(C)C)C1=CC=CC=C1 Chemical compound C=1N=C(N)N=C(N[C@@H]2CC[C@@H](O)CC2)C=1C(C(C)C)C1=CC=CC=C1 MSLVTEIEQSZWOQ-IBOPQAGSSA-N 0.000 claims 1
- ULIQHBLWKOFUEU-JOCQHMNTSA-N CC1=CC(Cl)=CC=C1OC1=CN=C(N)N=C1N[C@@H]1CC[C@@H](O)CC1 Chemical compound CC1=CC(Cl)=CC=C1OC1=CN=C(N)N=C1N[C@@H]1CC[C@@H](O)CC1 ULIQHBLWKOFUEU-JOCQHMNTSA-N 0.000 claims 1
- BQYXALFLESYWJM-HAQNSBGRSA-N COC1=CC=CC=C1OC1=CN=C(N)N=C1N[C@@H]1CC[C@@H](O)CC1 Chemical compound COC1=CC=CC=C1OC1=CN=C(N)N=C1N[C@@H]1CC[C@@H](O)CC1 BQYXALFLESYWJM-HAQNSBGRSA-N 0.000 claims 1
- BIYKYMVPQVBUQR-JOCQHMNTSA-N ClC1=CC(CC)=CC=C1OC1=CN=C(N)N=C1N[C@@H]1CC[C@@H](O)CC1 Chemical compound ClC1=CC(CC)=CC=C1OC1=CN=C(N)N=C1N[C@@H]1CC[C@@H](O)CC1 BIYKYMVPQVBUQR-JOCQHMNTSA-N 0.000 claims 1
- CWSYXNHHWZOGIY-MQMHXKEQSA-N N([C@@H]1CC[C@@H](CCO)CC1)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 Chemical compound N([C@@H]1CC[C@@H](CCO)CC1)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 CWSYXNHHWZOGIY-MQMHXKEQSA-N 0.000 claims 1
- FVLSXXIUFDULLP-SHTZXODSSA-N N([C@@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1CC1=CC=C(C(F)(F)F)C=C1 Chemical compound N([C@@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1CC1=CC=C(C(F)(F)F)C=C1 FVLSXXIUFDULLP-SHTZXODSSA-N 0.000 claims 1
- OSKCZMYMADHTLA-SHTZXODSSA-N N([C@@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1CC1=CC=C(Cl)C=C1 Chemical compound N([C@@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1CC1=CC=C(Cl)C=C1 OSKCZMYMADHTLA-SHTZXODSSA-N 0.000 claims 1
- KOENSRAZOKAFLF-WKILWMFISA-N N([C@@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1CCC1=CC=C(Cl)C=C1 Chemical compound N([C@@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1CCC1=CC=C(Cl)C=C1 KOENSRAZOKAFLF-WKILWMFISA-N 0.000 claims 1
- DOFAQPUACZJHFP-MGCOHNPYSA-N N([C@@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1OC1=C(Cl)C=C(Cl)C=C1Cl Chemical compound N([C@@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1OC1=C(Cl)C=C(Cl)C=C1Cl DOFAQPUACZJHFP-MGCOHNPYSA-N 0.000 claims 1
- NJHHXTOTAUXELU-MGCOHNPYSA-N N([C@@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1OC1=C(F)C=CC=C1F Chemical compound N([C@@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1OC1=C(F)C=CC=C1F NJHHXTOTAUXELU-MGCOHNPYSA-N 0.000 claims 1
- KYSVAXWLMIATAL-HAQNSBGRSA-N N([C@@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1OC1=CC=C(C(F)(F)F)C=C1 Chemical compound N([C@@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1OC1=CC=C(C(F)(F)F)C=C1 KYSVAXWLMIATAL-HAQNSBGRSA-N 0.000 claims 1
- BFTZWDWCSUINCX-HAQNSBGRSA-N N([C@@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1OC1=CC=C(F)C=C1 Chemical compound N([C@@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1OC1=CC=C(F)C=C1 BFTZWDWCSUINCX-HAQNSBGRSA-N 0.000 claims 1
- MLOBJYUFYMHJIQ-XYPYZODXSA-N N([C@@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1OC1=CC=C(F)C=C1F Chemical compound N([C@@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1OC1=CC=C(F)C=C1F MLOBJYUFYMHJIQ-XYPYZODXSA-N 0.000 claims 1
- UOWZSWQQJFJXHN-XYPYZODXSA-N N([C@@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1OC1=CC=C(OC(F)(F)F)C=C1 Chemical compound N([C@@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1OC1=CC=C(OC(F)(F)F)C=C1 UOWZSWQQJFJXHN-XYPYZODXSA-N 0.000 claims 1
- VFZZRHAKRDPSDS-MGCOHNPYSA-N N([C@@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1OC1=CC=CC(F)=C1F Chemical compound N([C@@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1OC1=CC=CC(F)=C1F VFZZRHAKRDPSDS-MGCOHNPYSA-N 0.000 claims 1
- JMSDTTTTZPDIOE-XYPYZODXSA-N N([C@@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1OC1=CC=CC=C1Cl Chemical compound N([C@@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1OC1=CC=CC=C1Cl JMSDTTTTZPDIOE-XYPYZODXSA-N 0.000 claims 1
- ARHKCFJEWRCWIA-HDJSIYSDSA-N N([C@@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1OCC1=CC=C(Cl)C=C1 Chemical compound N([C@@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1OCC1=CC=C(Cl)C=C1 ARHKCFJEWRCWIA-HDJSIYSDSA-N 0.000 claims 1
- CWSYXNHHWZOGIY-XBXGTLAGSA-N N([C@H]1CC[C@@H](CCO)CC1)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 Chemical compound N([C@H]1CC[C@@H](CCO)CC1)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 CWSYXNHHWZOGIY-XBXGTLAGSA-N 0.000 claims 1
- PUVKKJGFDNSRFV-BJHJDKERSA-N N([C@H]1CC[C@@H](CO)CC1)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 Chemical compound N([C@H]1CC[C@@H](CO)CC1)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 PUVKKJGFDNSRFV-BJHJDKERSA-N 0.000 claims 1
- IKTRZJYQWHAZHX-TXEJJXNPSA-N N([C@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 Chemical compound N([C@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 IKTRZJYQWHAZHX-TXEJJXNPSA-N 0.000 claims 1
- MJNSSMVAEUKNKG-SMDDNHRTSA-N [(1r,2r)-2-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclohexyl]methanol Chemical compound N([C@H]1[C@@H](CCCC1)CO)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 MJNSSMVAEUKNKG-SMDDNHRTSA-N 0.000 claims 1
- JODGBUBPTQJZDD-GXFFZTMASA-N [(1r,2r)-2-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclopentyl]methanol Chemical compound N([C@H]1[C@@H](CCC1)CO)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 JODGBUBPTQJZDD-GXFFZTMASA-N 0.000 claims 1
- SEBGNTONUCRAET-SMDDNHRTSA-N [(1r,2r)-2-[[5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclopentyl]methanol Chemical compound OC[C@@H]1CCC[C@H]1NC1=NC=NC=C1OC1=CC=C(Cl)C=C1 SEBGNTONUCRAET-SMDDNHRTSA-N 0.000 claims 1
- LNRLNLBTJNLFFK-QWRGUYRKSA-N [(1r,2r)-2-[[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]methyl]cyclobutyl]methanol Chemical compound C([C@H]1[C@@H](CC1)CO)NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 LNRLNLBTJNLFFK-QWRGUYRKSA-N 0.000 claims 1
- FVGSKTJMFZOOJA-UWVGGRQHSA-N [(1r,2r)-2-[[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]methyl]cyclopropyl]methanol Chemical compound C([C@H]1[C@@H](C1)CO)NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 FVGSKTJMFZOOJA-UWVGGRQHSA-N 0.000 claims 1
- APAYRJPJGAZZLB-QWRGUYRKSA-N [(1r,2r)-2-[[[5-(4-chlorophenoxy)pyrimidin-4-yl]amino]methyl]cyclopropyl]methanol Chemical compound OC[C@@H]1C[C@H]1CNC1=NC=NC=C1OC1=CC=C(Cl)C=C1 APAYRJPJGAZZLB-QWRGUYRKSA-N 0.000 claims 1
- DHCTZSXWTSHSGU-YPMHNXCESA-N [(1r,3s)-3-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclohexyl]methanol Chemical compound N([C@@H]1C[C@H](CO)CCC1)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 DHCTZSXWTSHSGU-YPMHNXCESA-N 0.000 claims 1
- LBAQIFSRGZCWMO-PWSUYJOCSA-N [(1r,3s)-3-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclopentyl]methanol Chemical compound N([C@@H]1C[C@H](CO)CC1)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 LBAQIFSRGZCWMO-PWSUYJOCSA-N 0.000 claims 1
- MJNSSMVAEUKNKG-BXUZGUMPSA-N [(1s,2r)-2-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclohexyl]methanol Chemical compound N([C@H]1[C@H](CCCC1)CO)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 MJNSSMVAEUKNKG-BXUZGUMPSA-N 0.000 claims 1
- JODGBUBPTQJZDD-ZWNOBZJWSA-N [(1s,2r)-2-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclopentyl]methanol Chemical compound N([C@H]1[C@H](CCC1)CO)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 JODGBUBPTQJZDD-ZWNOBZJWSA-N 0.000 claims 1
- LNRLNLBTJNLFFK-WDEREUQCSA-N [(1s,2r)-2-[[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]methyl]cyclobutyl]methanol Chemical compound C([C@H]1[C@H](CC1)CO)NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 LNRLNLBTJNLFFK-WDEREUQCSA-N 0.000 claims 1
- FVGSKTJMFZOOJA-VHSXEESVSA-N [(1s,2r)-2-[[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]methyl]cyclopropyl]methanol Chemical compound C([C@H]1[C@H](C1)CO)NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 FVGSKTJMFZOOJA-VHSXEESVSA-N 0.000 claims 1
- DHCTZSXWTSHSGU-AAEUAGOBSA-N [(1s,3s)-3-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclohexyl]methanol Chemical compound N([C@@H]1C[C@@H](CO)CCC1)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 DHCTZSXWTSHSGU-AAEUAGOBSA-N 0.000 claims 1
- LBAQIFSRGZCWMO-JQWIXIFHSA-N [(1s,3s)-3-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclopentyl]methanol Chemical compound N([C@@H]1C[C@@H](CO)CC1)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 LBAQIFSRGZCWMO-JQWIXIFHSA-N 0.000 claims 1
- YLURGOMFXXLHHB-JSGCOSHPSA-N [(1s,3s)-3-[[5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclohexyl]methanol Chemical compound C1[C@@H](CO)CCC[C@@H]1NC1=NC=NC=C1OC1=CC=C(Cl)C=C1 YLURGOMFXXLHHB-JSGCOSHPSA-N 0.000 claims 1
- ZPCZZQQECMEKEV-AAEUAGOBSA-N [(1s,3s)-3-[[5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclopentyl]methanol Chemical compound C1[C@@H](CO)CC[C@@H]1NC1=NC=NC=C1OC1=CC=C(Cl)C=C1 ZPCZZQQECMEKEV-AAEUAGOBSA-N 0.000 claims 1
- KCQGPSWBFIIMTF-UHFFFAOYSA-N [1-[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]pyrrolidin-3-yl]methanol Chemical compound C1CC(CO)CN1C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 KCQGPSWBFIIMTF-UHFFFAOYSA-N 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- KFIIYRMNOGZLTA-UHFFFAOYSA-N n-[2-amino-5-(2,4-dichlorophenoxy)pyrimidin-4-yl]-n-cyclohexylhydroxylamine Chemical compound C1CCCCC1N(O)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1Cl KFIIYRMNOGZLTA-UHFFFAOYSA-N 0.000 claims 1
- ZJWZSCCEWICLLD-UHFFFAOYSA-N n-[2-amino-5-(2,4-dichlorophenoxy)pyrimidin-4-yl]-n-phenylhydroxylamine Chemical compound C=1C=CC=CC=1N(O)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1Cl ZJWZSCCEWICLLD-UHFFFAOYSA-N 0.000 claims 1
- VMXXHDGOSALVBA-UHFFFAOYSA-N n-[2-amino-5-(4-bromophenoxy)pyrimidin-4-yl]-n-cyclohexylhydroxylamine Chemical compound C1CCCCC1N(O)C1=NC(N)=NC=C1OC1=CC=C(Br)C=C1 VMXXHDGOSALVBA-UHFFFAOYSA-N 0.000 claims 1
- GULXQWAAUYVMGE-UHFFFAOYSA-N n-[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]-n-cyclohexylhydroxylamine Chemical compound C1CCCCC1N(O)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 GULXQWAAUYVMGE-UHFFFAOYSA-N 0.000 claims 1
- UCXSKGCSYFOJCR-UHFFFAOYSA-N n-[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]-n-phenylhydroxylamine Chemical compound C=1C=CC=CC=1N(O)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 UCXSKGCSYFOJCR-UHFFFAOYSA-N 0.000 claims 1
- DPYSYAMKXLMOQB-UHFFFAOYSA-N n-[2-amino-5-(4-ethylphenoxy)pyrimidin-4-yl]-n-cyclohexylhydroxylamine Chemical compound C1=CC(CC)=CC=C1OC1=CN=C(N)N=C1N(O)C1CCCCC1 DPYSYAMKXLMOQB-UHFFFAOYSA-N 0.000 claims 1
- ODBOXCYBWHONTF-UHFFFAOYSA-N n-[2-amino-5-(4-ethylphenoxy)pyrimidin-4-yl]-n-phenylhydroxylamine Chemical compound C1=CC(CC)=CC=C1OC1=CN=C(N)N=C1N(O)C1=CC=CC=C1 ODBOXCYBWHONTF-UHFFFAOYSA-N 0.000 claims 1
- JLWHRLWLQCYYHM-UHFFFAOYSA-N n-[2-amino-5-(4-methylphenoxy)pyrimidin-4-yl]-n-cyclohexylhydroxylamine Chemical compound C1=CC(C)=CC=C1OC1=CN=C(N)N=C1N(O)C1CCCCC1 JLWHRLWLQCYYHM-UHFFFAOYSA-N 0.000 claims 1
- CBKFRXWRJRYKCV-UHFFFAOYSA-N n-[2-amino-5-(4-methylphenoxy)pyrimidin-4-yl]-n-phenylhydroxylamine Chemical compound C1=CC(C)=CC=C1OC1=CN=C(N)N=C1N(O)C1=CC=CC=C1 CBKFRXWRJRYKCV-UHFFFAOYSA-N 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 18
- 238000000034 method Methods 0.000 abstract description 17
- 208000025966 Neurological disease Diseases 0.000 abstract description 4
- 230000002093 peripheral effect Effects 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 74
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 67
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 66
- 239000000243 solution Substances 0.000 description 44
- 239000000203 mixture Substances 0.000 description 43
- 239000007787 solid Substances 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 26
- 235000019439 ethyl acetate Nutrition 0.000 description 25
- 229940093499 ethyl acetate Drugs 0.000 description 24
- 108010025020 Nerve Growth Factor Proteins 0.000 description 21
- 102000015336 Nerve Growth Factor Human genes 0.000 description 21
- 229940053128 nerve growth factor Drugs 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 238000009472 formulation Methods 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000003756 stirring Methods 0.000 description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 239000004480 active ingredient Substances 0.000 description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 14
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 13
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 10
- 229910052938 sodium sulfate Inorganic materials 0.000 description 10
- 235000011152 sodium sulphate Nutrition 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 238000001704 evaporation Methods 0.000 description 9
- 230000008020 evaporation Effects 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- 230000014511 neuron projection development Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000006188 syrup Substances 0.000 description 8
- 235000020357 syrup Nutrition 0.000 description 8
- 239000003039 volatile agent Substances 0.000 description 8
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- ZTNYLJYJRPBIKF-UHFFFAOYSA-N 5-(4-ethylphenoxy)-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound C1=CC(CC)=CC=C1OC1=CN=C(S)NC1=O ZTNYLJYJRPBIKF-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 4
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000002480 mineral oil Substances 0.000 description 4
- 235000010446 mineral oil Nutrition 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- MICLTPPSCUXHJT-UHFFFAOYSA-M potassium;4-[3-(6-oxo-3h-purin-9-yl)propanoylamino]benzoate Chemical compound [K+].C1=CC(C(=O)[O-])=CC=C1NC(=O)CCN1C(NC=NC2=O)=C2N=C1 MICLTPPSCUXHJT-UHFFFAOYSA-M 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 4
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 3
- MHSKQBMDUWBJRN-UHFFFAOYSA-N 2-amino-5-(4-chlorophenoxy)-1h-pyrimidin-6-one Chemical compound N1C(N)=NC(=O)C(OC=2C=CC(Cl)=CC=2)=C1 MHSKQBMDUWBJRN-UHFFFAOYSA-N 0.000 description 3
- RKTQEVMZBCBOSB-UHFFFAOYSA-N 4-aminocyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1CCC(O)CC1 RKTQEVMZBCBOSB-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- IKTRZJYQWHAZHX-HAQNSBGRSA-N N([C@@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 Chemical compound N([C@@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 IKTRZJYQWHAZHX-HAQNSBGRSA-N 0.000 description 3
- 208000028389 Nerve injury Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000001713 cholinergic effect Effects 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- LDYXFZJKLMVFSI-UHFFFAOYSA-N n'-[4-chloro-5-(4-chlorophenoxy)pyrimidin-2-yl]-n,n-di(propan-2-yl)methanimidamide Chemical compound ClC1=NC(N=CN(C(C)C)C(C)C)=NC=C1OC1=CC=C(Cl)C=C1 LDYXFZJKLMVFSI-UHFFFAOYSA-N 0.000 description 3
- UNBDDZDKBWPHAX-UHFFFAOYSA-N n,n-di(propan-2-yl)formamide Chemical compound CC(C)N(C=O)C(C)C UNBDDZDKBWPHAX-UHFFFAOYSA-N 0.000 description 3
- 230000008764 nerve damage Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 208000027232 peripheral nervous system disease Diseases 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000003936 working memory Effects 0.000 description 3
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- YHMOOSOFQSMTLT-ZGTDKVADSA-N Cl.C1=CC(CC)=CC=C1OC1=CN=CN=C1N[C@@H]1CC[C@@H](O)CC1 Chemical compound Cl.C1=CC(CC)=CC=C1OC1=CN=CN=C1N[C@@H]1CC[C@@H](O)CC1 YHMOOSOFQSMTLT-ZGTDKVADSA-N 0.000 description 2
- STRQGZNZEBSOEZ-GJTSMBTKSA-N Cl.N([C@@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 Chemical compound Cl.N([C@@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 STRQGZNZEBSOEZ-GJTSMBTKSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- PNKUSGQVOMIXLU-UHFFFAOYSA-N Formamidine Chemical compound NC=N PNKUSGQVOMIXLU-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229940100228 acetyl coenzyme a Drugs 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000007963 capsule composition Substances 0.000 description 2
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 210000002932 cholinergic neuron Anatomy 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- QULRDJFRGVHKLN-UHFFFAOYSA-N ethyl 2-(4-chlorophenoxy)acetate Chemical compound CCOC(=O)COC1=CC=C(Cl)C=C1 QULRDJFRGVHKLN-UHFFFAOYSA-N 0.000 description 2
- CMUWQYNXOALYPI-UHFFFAOYSA-N ethyl 2-(4-ethylphenoxy)acetate Chemical compound CCOC(=O)COC1=CC=C(CC)C=C1 CMUWQYNXOALYPI-UHFFFAOYSA-N 0.000 description 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- ZUFVXZVXEJHHBN-UHFFFAOYSA-N hydron;1,2,3,4-tetrahydroacridin-9-amine;chloride Chemical compound [Cl-].C1=CC=C2C([NH3+])=C(CCCC3)C3=NC2=C1 ZUFVXZVXEJHHBN-UHFFFAOYSA-N 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- FTCYIGBVOHNHCD-UHFFFAOYSA-N isaxonine Chemical compound CC(C)NC1=NC=CC=N1 FTCYIGBVOHNHCD-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000003551 muscarinic effect Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 229940080313 sodium starch Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229960001685 tacrine Drugs 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- SODPIMGUZLOIPE-UHFFFAOYSA-N (4-chlorophenoxy)acetic acid Chemical compound OC(=O)COC1=CC=C(Cl)C=C1 SODPIMGUZLOIPE-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- MRBFGEHILMYPTF-UHFFFAOYSA-N 1-(2-Pyrimidyl)piperazine Chemical class C1CNCCN1C1=NC=CC=N1 MRBFGEHILMYPTF-UHFFFAOYSA-N 0.000 description 1
- KLCRXJVUAKJPDB-UHFFFAOYSA-N 1-[2-amino-5-[(4-ethylphenyl)methyl]pyrimidin-4-yl]piperidin-4-one 1-[2-amino-5-[(4-methylphenyl)methyl]pyrimidin-4-yl]piperidin-4-one 1-[2-amino-5-[[4-(trifluoromethyl)phenyl]methyl]pyrimidin-4-yl]piperidin-4-one Chemical compound NC1=NC=C(C(=N1)N1CCC(CC1)=O)CC1=CC=C(C=C1)CC.NC1=NC=C(C(=N1)N1CCC(CC1)=O)CC1=CC=C(C=C1)C.NC1=NC=C(C(=N1)N1CCC(CC1)=O)CC1=CC=C(C=C1)C(F)(F)F KLCRXJVUAKJPDB-UHFFFAOYSA-N 0.000 description 1
- CAMKSAJWYZLGJK-BAUSSPIASA-N 1-[[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]methyl]cyclopropan-1-ol;[(1s,2r)-2-[[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]methyl]cyclopropyl]methanol Chemical compound C1CC1(O)CNC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1.C([C@H]1[C@H](C1)CO)NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 CAMKSAJWYZLGJK-BAUSSPIASA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- VMKUHZBJUWCWOR-SWLSCSKDSA-N 2-[(1s,2r)-2-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclohexyl]ethanol Chemical compound N([C@H]1[C@@H](CCCC1)CCO)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 VMKUHZBJUWCWOR-SWLSCSKDSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- WKKJRGITANXXJN-UHFFFAOYSA-N 2-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclopentan-1-one 3-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclopentan-1-one Chemical compound NC1=NC=C(C(=N1)NC1C(CCC1)=O)OC1=CC=C(C=C1)Cl.NC1=NC=C(C(=N1)NC1CC(CC1)=O)OC1=CC=C(C=C1)Cl WKKJRGITANXXJN-UHFFFAOYSA-N 0.000 description 1
- XOFNLOOXSPLLNB-UHFFFAOYSA-N 2-amino-5-(2,4-dichlorophenoxy)-1h-pyrimidin-6-one Chemical compound N1C(N)=NC(=O)C(OC=2C(=CC(Cl)=CC=2)Cl)=C1 XOFNLOOXSPLLNB-UHFFFAOYSA-N 0.000 description 1
- JJKWHOSQTYYFAE-UHFFFAOYSA-N 2-methoxyacetyl chloride Chemical compound COCC(Cl)=O JJKWHOSQTYYFAE-UHFFFAOYSA-N 0.000 description 1
- ZUKZBDWLSDJNLE-UHFFFAOYSA-N 4-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]cyclohexan-1-one;hydrochloride Chemical compound Cl.C1CC(=O)CCC1NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 ZUKZBDWLSDJNLE-UHFFFAOYSA-N 0.000 description 1
- UCJFPRVDMMRJQF-UHFFFAOYSA-N 4-[[2-amino-5-(4-chlorophenoxy)pyrimidin-4-yl]amino]phenol;hydrochloride Chemical compound Cl.C=1C=C(O)C=CC=1NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 UCJFPRVDMMRJQF-UHFFFAOYSA-N 0.000 description 1
- BWPNNVWLMKRYQJ-UHFFFAOYSA-N 4-chloro-5-(4-ethylphenoxy)pyrimidine Chemical compound C1=CC(CC)=CC=C1OC1=CN=CN=C1Cl BWPNNVWLMKRYQJ-UHFFFAOYSA-N 0.000 description 1
- QGNGOGOOPUYKMC-UHFFFAOYSA-N 4-hydroxy-6-methylaniline Chemical compound CC1=CC(O)=CC=C1N QGNGOGOOPUYKMC-UHFFFAOYSA-N 0.000 description 1
- APTANHMYYZPGNW-UHFFFAOYSA-N 5-(4-chlorophenoxy)pyrimidine-2,4-diamine Chemical compound NC1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1 APTANHMYYZPGNW-UHFFFAOYSA-N 0.000 description 1
- BHCOEOHCUJFIQU-UHFFFAOYSA-N 5-(4-ethylphenoxy)-1h-pyrimidin-6-one Chemical compound C1=CC(CC)=CC=C1OC1=CN=CNC1=O BHCOEOHCUJFIQU-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 101100219283 Amycolatopsis orientalis cyp165C4 gene Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- VBYDUMPNEINWHE-UHFFFAOYSA-N CC1=CC=C(OC=2C(NC(=NC2)N)=O)C=C1.O(C1=CC=CC=C1)C=1C(NC(=NC1)N)=O Chemical compound CC1=CC=C(OC=2C(NC(=NC2)N)=O)C=C1.O(C1=CC=CC=C1)C=1C(NC(=NC1)N)=O VBYDUMPNEINWHE-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- PCRVQKDJQSPVPF-PFWPSKEQSA-N Cl.N([C@@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1Cl Chemical compound Cl.N([C@@H]1CC[C@@H](O)CC1)C1=NC(N)=NC=C1OC1=CC=C(Cl)C=C1Cl PCRVQKDJQSPVPF-PFWPSKEQSA-N 0.000 description 1
- ADJXRYIHUAWLMZ-CLVGDUISSA-N ClC1=NC(=NC=C1OC1=CC=C(C=C1)Cl)N=CN(C(C)C)C(C)C.NC1=NC=C(C(=N1)N[C@@H]1CC[C@H](CC1)O)OC1=CC=C(C=C1)Cl Chemical compound ClC1=NC(=NC=C1OC1=CC=C(C=C1)Cl)N=CN(C(C)C)C(C)C.NC1=NC=C(C(=N1)N[C@@H]1CC[C@H](CC1)O)OC1=CC=C(C=C1)Cl ADJXRYIHUAWLMZ-CLVGDUISSA-N 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 235000008247 Echinochloa frumentacea Nutrition 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 206010027374 Mental impairment Diseases 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- JKYVOOSLUWPFIA-WGSAOQKQSA-N N([C@@H]1CC[C@@H](O)CC1)C1=NC(N=CN(C(C)C)C(C)C)=NC=C1OC1=CC=C(Cl)C=C1 Chemical compound N([C@@H]1CC[C@@H](O)CC1)C1=NC(N=CN(C(C)C)C(C)C)=NC=C1OC1=CC=C(Cl)C=C1 JKYVOOSLUWPFIA-WGSAOQKQSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- IJPOQJVNMUIARE-UHFFFAOYSA-N NC1=NC=C(C(=N1)N(C1CCCCC1)O)OC1=CC=C(C=C1)Br.NC1=NC=C(C(=N1)N(C1CCCCC1)O)OC1=C(C=C(C=C1)Cl)Cl Chemical compound NC1=NC=C(C(=N1)N(C1CCCCC1)O)OC1=CC=C(C=C1)Br.NC1=NC=C(C(=N1)N(C1CCCCC1)O)OC1=C(C=C(C=C1)Cl)Cl IJPOQJVNMUIARE-UHFFFAOYSA-N 0.000 description 1
- WOZINGSFLWKKPV-UHFFFAOYSA-N NC1=NC=C(C(=N1)N(CCO)CO)OC1=CC=C(C=C1)Cl.NC1=NC=C(C(=N1)NC(CO)(C)C)OC1=CC=C(C=C1)Cl Chemical compound NC1=NC=C(C(=N1)N(CCO)CO)OC1=CC=C(C=C1)Cl.NC1=NC=C(C(=N1)NC(CO)(C)C)OC1=CC=C(C=C1)Cl WOZINGSFLWKKPV-UHFFFAOYSA-N 0.000 description 1
- BXLCWDHUYACZMY-UHFFFAOYSA-N NC1=NC=C(C(=N1)N1CCC(CC1)=O)CC1=C(C=C(C=C1)C)Cl.NC1=NC=C(C(=N1)N1CCC(CC1)=O)CC1=C(C=C(C=C1)C(F)(F)F)Cl Chemical compound NC1=NC=C(C(=N1)N1CCC(CC1)=O)CC1=C(C=C(C=C1)C)Cl.NC1=NC=C(C(=N1)N1CCC(CC1)=O)CC1=C(C=C(C=C1)C(F)(F)F)Cl BXLCWDHUYACZMY-UHFFFAOYSA-N 0.000 description 1
- QEQJPDASALYONX-UHFFFAOYSA-N NC1=NC=C(C(=N1)N1CCC(CC1)=O)CC1=C(C=C(C=C1)Cl)Cl.NC1=NC=C(C(=N1)N1CC(CCC1)=O)CC1=CC=C(C=C1)CC.NC1=NC=C(C(=N1)N1CC(CCC1)=O)CC1=CC=C(C=C1)C Chemical compound NC1=NC=C(C(=N1)N1CCC(CC1)=O)CC1=C(C=C(C=C1)Cl)Cl.NC1=NC=C(C(=N1)N1CC(CCC1)=O)CC1=CC=C(C=C1)CC.NC1=NC=C(C(=N1)N1CC(CCC1)=O)CC1=CC=C(C=C1)C QEQJPDASALYONX-UHFFFAOYSA-N 0.000 description 1
- XVRMBHIAMJENBE-UHFFFAOYSA-N NC1=NC=C(C(=N1)N1CCC(CC1)=O)CC1=CC(=CC=C1)C(F)(F)F.NC1=NC=C(C(=N1)N1CC(CCC1)=O)CC1=CC=C(C=C1)Br.NC1=NC=C(C(=N1)N1CC(CCC1)=O)CC1=CC=C(C=C1)Cl Chemical compound NC1=NC=C(C(=N1)N1CCC(CC1)=O)CC1=CC(=CC=C1)C(F)(F)F.NC1=NC=C(C(=N1)N1CC(CCC1)=O)CC1=CC=C(C=C1)Br.NC1=NC=C(C(=N1)N1CC(CCC1)=O)CC1=CC=C(C=C1)Cl XVRMBHIAMJENBE-UHFFFAOYSA-N 0.000 description 1
- WUFFMMLQYZOLSV-ADUSHPDTSA-N NC1=NC=C(C(=N1)N1CCC(CC1)=O)CC1=CC=C(C=C1)Br.NC1=NC=C(C(=N1)N1CCC(CC1)=O)CC1=CC=C(C=C1)Cl.NC1=NC=C(C(=N1)N[C@@H]1CC[C@H](CC1)O)C(C1=CC=CC=C1)C(C)C Chemical compound NC1=NC=C(C(=N1)N1CCC(CC1)=O)CC1=CC=C(C=C1)Br.NC1=NC=C(C(=N1)N1CCC(CC1)=O)CC1=CC=C(C=C1)Cl.NC1=NC=C(C(=N1)N[C@@H]1CC[C@H](CC1)O)C(C1=CC=CC=C1)C(C)C WUFFMMLQYZOLSV-ADUSHPDTSA-N 0.000 description 1
- ZSDZZQSTOXHBOW-UHFFFAOYSA-N NC1=NC=C(C(=N1)NC(CO)(CO)CO)OC1=CC=C(C=C1)Cl.NC1=NC=C(C(=N1)NC(CO)CCO)OC1=CC=C(C=C1)Cl Chemical compound NC1=NC=C(C(=N1)NC(CO)(CO)CO)OC1=CC=C(C=C1)Cl.NC1=NC=C(C(=N1)NC(CO)CCO)OC1=CC=C(C=C1)Cl ZSDZZQSTOXHBOW-UHFFFAOYSA-N 0.000 description 1
- FNMOWKCSNMQOJM-UHFFFAOYSA-N NC1=NC=C(C(=N1)NC(CO)C)OC1=CC=C(C=C1)Cl.NC1=NC=C(C(=N1)NCCCCCCO)OC1=CC=C(C=C1)Cl Chemical compound NC1=NC=C(C(=N1)NC(CO)C)OC1=CC=C(C=C1)Cl.NC1=NC=C(C(=N1)NCCCCCCO)OC1=CC=C(C=C1)Cl FNMOWKCSNMQOJM-UHFFFAOYSA-N 0.000 description 1
- DVKZNHKHXGMMGQ-UHFFFAOYSA-N NC1=NC=C(C(=N1)NC1C(CCCC1)=O)OC1=CC=C(C=C1)Br.NC1=NC=C(C(=N1)NC1C(CCCC1)=O)OC1=C(C=C(C=C1)Cl)Cl Chemical compound NC1=NC=C(C(=N1)NC1C(CCCC1)=O)OC1=CC=C(C=C1)Br.NC1=NC=C(C(=N1)NC1C(CCCC1)=O)OC1=C(C=C(C=C1)Cl)Cl DVKZNHKHXGMMGQ-UHFFFAOYSA-N 0.000 description 1
- LJCPARCREIGODI-UHFFFAOYSA-N NC1=NC=C(C(=N1)NCCO)OC1=CC=C(C=C1)Br.NC1=NC=C(C(=N1)NCCO)OC1=C(C=C(C=C1)Cl)Cl.NC1=NC=C(C(=N1)NCCO)OC1=CC=C(C=C1)Cl Chemical compound NC1=NC=C(C(=N1)NCCO)OC1=CC=C(C=C1)Br.NC1=NC=C(C(=N1)NCCO)OC1=C(C=C(C=C1)Cl)Cl.NC1=NC=C(C(=N1)NCCO)OC1=CC=C(C=C1)Cl LJCPARCREIGODI-UHFFFAOYSA-N 0.000 description 1
- HYKOMKQMBZPTOK-NLFWCWCMSA-N NC1=NC=C(C(=N1)NC[C@@H]1C[C@@H](C1)CO)OC1=CC=C(C=C1)Cl.NC1=NC=C(C(=N1)NC[C@H]1[C@H](CC1)CO)OC1=CC=C(C=C1)Cl Chemical compound NC1=NC=C(C(=N1)NC[C@@H]1C[C@@H](C1)CO)OC1=CC=C(C=C1)Cl.NC1=NC=C(C(=N1)NC[C@H]1[C@H](CC1)CO)OC1=CC=C(C=C1)Cl HYKOMKQMBZPTOK-NLFWCWCMSA-N 0.000 description 1
- WHQZOPVYVUFRQW-NTYSSDSPSA-N NC1=NC=C(C(=N1)NC[C@@H]1C[C@H](C1)O)OC1=CC=C(C=C1)Cl.NC1=NC=C(C(=N1)NC[C@H]1[C@@H](CC1)O)OC1=CC=C(C=C1)Cl Chemical compound NC1=NC=C(C(=N1)NC[C@@H]1C[C@H](C1)O)OC1=CC=C(C=C1)Cl.NC1=NC=C(C(=N1)NC[C@H]1[C@@H](CC1)O)OC1=CC=C(C=C1)Cl WHQZOPVYVUFRQW-NTYSSDSPSA-N 0.000 description 1
- GQKODNGTVPCTDC-QGJYWMLTSA-N NC1=NC=C(C(=N1)NC[C@H]1[C@@H](CC1)CO)OC1=CC=C(C=C1)Cl.NC1=NC=C(C(=N1)NC[C@H]1[C@H](CCC1)O)OC1=CC=C(C=C1)Cl Chemical compound NC1=NC=C(C(=N1)NC[C@H]1[C@@H](CC1)CO)OC1=CC=C(C=C1)Cl.NC1=NC=C(C(=N1)NC[C@H]1[C@H](CCC1)O)OC1=CC=C(C=C1)Cl GQKODNGTVPCTDC-QGJYWMLTSA-N 0.000 description 1
- VDYGYBMPOMDNLB-IUJYDJBPSA-N NC1=NC=C(C(=N1)N[C@@H]1CC[C@H](CC1)O)OC1=C(C=CC=C1F)F.NC1=NC=C(C(=N1)N[C@@H]1CC[C@H](CC1)O)OC1=C(C=C(C=C1)F)F Chemical compound NC1=NC=C(C(=N1)N[C@@H]1CC[C@H](CC1)O)OC1=C(C=CC=C1F)F.NC1=NC=C(C(=N1)N[C@@H]1CC[C@H](CC1)O)OC1=C(C=C(C=C1)F)F VDYGYBMPOMDNLB-IUJYDJBPSA-N 0.000 description 1
- FAAMCNDXFCQUEG-GXZUGXAESA-N NC1=NC=C(C(=N1)N[C@@H]1CC[C@H](CC1)O)OC1=CC=C(C=C1)C.NC1=NC=C(C(=N1)N[C@@H]1CC[C@H](CC1)O)OC1=CC=C(C=C1)C(F)(F)F Chemical compound NC1=NC=C(C(=N1)N[C@@H]1CC[C@H](CC1)O)OC1=CC=C(C=C1)C.NC1=NC=C(C(=N1)N[C@@H]1CC[C@H](CC1)O)OC1=CC=C(C=C1)C(F)(F)F FAAMCNDXFCQUEG-GXZUGXAESA-N 0.000 description 1
- YTSGVUMVAJRPEZ-DQJDZKJGSA-N NC1=NC=C(C(=N1)N[C@@H]1C[C@H](CCC1)CCO)OC1=CC=C(C=C1)Cl.NC1=NC=C(C(=N1)N[C@@H]1CC[C@H](CC1)CCO)OC1=CC=C(C=C1)Cl Chemical compound NC1=NC=C(C(=N1)N[C@@H]1C[C@H](CCC1)CCO)OC1=CC=C(C=C1)Cl.NC1=NC=C(C(=N1)N[C@@H]1CC[C@H](CC1)CCO)OC1=CC=C(C=C1)Cl YTSGVUMVAJRPEZ-DQJDZKJGSA-N 0.000 description 1
- JOADEFOPPGDRMF-ZXNVQPPNSA-N NC1=NC=C(C(=N1)N[C@H]1[C@@H](CCC1)O)OC1=CC=C(C=C1)Cl.NC1=NC=C(C(=N1)N[C@@H]1C[C@H](CC1)O)OC1=CC=C(C=C1)Cl Chemical compound NC1=NC=C(C(=N1)N[C@H]1[C@@H](CCC1)O)OC1=CC=C(C=C1)Cl.NC1=NC=C(C(=N1)N[C@@H]1C[C@H](CC1)O)OC1=CC=C(C=C1)Cl JOADEFOPPGDRMF-ZXNVQPPNSA-N 0.000 description 1
- BWFUFFLODMLUEA-JZNDBVEYSA-N NC1=NC=C(C(=N1)N[C@H]1[C@H](CCC1)CCO)OC1=CC=C(C=C1)Cl.NC1=NC=C(C(=N1)N[C@@H]1C[C@@H](CC1)CCO)OC1=CC=C(C=C1)Cl Chemical group NC1=NC=C(C(=N1)N[C@H]1[C@H](CCC1)CCO)OC1=CC=C(C=C1)Cl.NC1=NC=C(C(=N1)N[C@@H]1C[C@@H](CC1)CCO)OC1=CC=C(C=C1)Cl BWFUFFLODMLUEA-JZNDBVEYSA-N 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 102000000728 Nerve growth factor-like Human genes 0.000 description 1
- 108050008149 Nerve growth factor-like Proteins 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- MASVCBBIUQRUKL-UHFFFAOYSA-N POPOP Chemical compound C=1N=C(C=2C=CC(=CC=2)C=2OC(=CN=2)C=2C=CC=CC=2)OC=1C1=CC=CC=C1 MASVCBBIUQRUKL-UHFFFAOYSA-N 0.000 description 1
- 240000004072 Panicum sumatrense Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- STSCVKRWJPWALQ-UHFFFAOYSA-N TRIFLUOROACETIC ACID ETHYL ESTER Chemical compound CCOC(=O)C(F)(F)F STSCVKRWJPWALQ-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- WTBGLIYOMCSSER-UHFFFAOYSA-N [N].Cl.NC1=NC=C(C(=N1)NC1=CC=C(C=C1)O)OC1=CC=C(C=C1)Cl Chemical compound [N].Cl.NC1=NC=C(C(=N1)NC1=CC=C(C=C1)O)OC1=CC=C(C=C1)Cl WTBGLIYOMCSSER-UHFFFAOYSA-N 0.000 description 1
- VCHQHNKBZVBQGJ-UHFFFAOYSA-N [N].NC1=NC=C(C(=N1)NC1=C(C=C(C=C1)O)C)OC1=CC=C(C=C1)Cl Chemical compound [N].NC1=NC=C(C(=N1)NC1=C(C=C(C=C1)O)C)OC1=CC=C(C=C1)Cl VCHQHNKBZVBQGJ-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 201000003352 adrenal gland pheochromocytoma Diseases 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940082992 antihypertensives mao inhibitors Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940039856 aricept Drugs 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- STIAPHVBRDNOAJ-UHFFFAOYSA-N carbamimidoylazanium;carbonate Chemical compound NC(N)=N.NC(N)=N.OC(O)=O STIAPHVBRDNOAJ-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- QQVDYSUDFZZPSU-UHFFFAOYSA-M chloromethylidene(dimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)=CCl QQVDYSUDFZZPSU-UHFFFAOYSA-M 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- IAQWMWUKBQPOIY-UHFFFAOYSA-N chromium(4+);oxygen(2-) Chemical compound [O-2].[O-2].[Cr+4] IAQWMWUKBQPOIY-UHFFFAOYSA-N 0.000 description 1
- AYTAKQFHWFYBMA-UHFFFAOYSA-N chromium(IV) oxide Inorganic materials O=[Cr]=O AYTAKQFHWFYBMA-UHFFFAOYSA-N 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000006312 cyclopentyl amino group Chemical group [H]N(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- AAUXUGPBQMWARN-UHFFFAOYSA-N ethyl 2-(4-chlorophenoxy)-3-oxopropanoate Chemical compound CCOC(=O)C(C=O)OC1=CC=C(Cl)C=C1 AAUXUGPBQMWARN-UHFFFAOYSA-N 0.000 description 1
- DLBFBRNHBOXKPK-UHFFFAOYSA-N ethyl 2-(4-ethylphenoxy)-3-oxopropanoate Chemical compound CCOC(=O)C(C=O)OC1=CC=C(CC)C=C1 DLBFBRNHBOXKPK-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical class CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229950002643 isaxonine Drugs 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- OVEHNNQXLPJPPL-UHFFFAOYSA-N lithium;n-propan-2-ylpropan-2-amine Chemical compound [Li].CC(C)NC(C)C OVEHNNQXLPJPPL-UHFFFAOYSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 230000007074 memory dysfunction Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- UTUSRXQKLZWLEN-UHFFFAOYSA-N n'-[4-chloro-5-(2,4-dichlorophenoxy)pyrimidin-2-yl]-n,n-di(propan-2-yl)methanimidamide Chemical compound ClC1=NC(N=CN(C(C)C)C(C)C)=NC=C1OC1=CC=C(Cl)C=C1Cl UTUSRXQKLZWLEN-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000035771 neuroregeneration Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 239000000181 nicotinic agonist Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
- 229960001697 physostigmine Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- VFIZBHJTOHUOEK-UHFFFAOYSA-N s-ethylisothiourea Chemical compound CCSC(N)=N VFIZBHJTOHUOEK-UHFFFAOYSA-N 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 230000006886 spatial memory Effects 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- MDCWDBMBZLORER-UHFFFAOYSA-N triphenyl borate Chemical compound C=1C=CC=CC=1OB(OC=1C=CC=CC=1)OC1=CC=CC=C1 MDCWDBMBZLORER-UHFFFAOYSA-N 0.000 description 1
- 230000031836 visual learning Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/288,495 | 1999-04-08 | ||
| US09/288,495 US6583148B1 (en) | 1999-04-08 | 1999-04-08 | Neurotrophic substituted pyrimidines |
| PCT/US2000/009108 WO2000061562A1 (en) | 1999-04-08 | 2000-04-06 | Neurotrophic substituted pyrimidines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2368843A1 CA2368843A1 (en) | 2000-10-19 |
| CA2368843C true CA2368843C (en) | 2009-10-20 |
Family
ID=23107364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002368843A Expired - Fee Related CA2368843C (en) | 1999-04-08 | 2000-04-06 | Neurotrophic substituted pyrimidines |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6583148B1 (enExample) |
| EP (1) | EP1165523B1 (enExample) |
| JP (1) | JP4743463B2 (enExample) |
| AT (1) | ATE377592T1 (enExample) |
| AU (1) | AU4331400A (enExample) |
| CA (1) | CA2368843C (enExample) |
| DE (1) | DE60037013T2 (enExample) |
| WO (1) | WO2000061562A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1303495T3 (da) * | 2000-07-24 | 2010-09-20 | Krenitsky Pharmaceuticals Inc | Substituerede 5-alkylnylpyrimidiner med neurotrofisk aktivitet |
| BR0307665A (pt) | 2002-02-13 | 2005-01-04 | Hoffmann La Roche | Compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou profilaxia de enfermidades associadas com dpp iv e utilização dos compostos |
| JP2005232081A (ja) * | 2004-02-19 | 2005-09-02 | Bayer Cropscience Ag | ベンジルピリミジン誘導体の農園芸用殺菌剤としての利用 |
| PL1725540T3 (pl) * | 2004-03-05 | 2013-02-28 | Hoffmann La Roche | Diaminopirymidyny jako antagoniści p2x3 i p2x2/3 |
| EP2594318B1 (en) * | 2005-04-15 | 2020-06-10 | University Of North Carolina At Chapel Hill | Methods of facilitating cell survival using neurotrophin mimetics |
| US20110230479A1 (en) * | 2005-04-15 | 2011-09-22 | Longo Frank M | Neurotrophin mimetics and uses thereof |
| EP1893192A4 (en) | 2005-06-08 | 2010-03-31 | Univ North Carolina | METHOD FOR ENABLING SURVIVAL OF NERVE CELLS BASED ON NON-PEPTIDIC AND PEPTIDIC BDNF NEUROTROPHINE MIMETICS |
| KR101012926B1 (ko) * | 2005-09-01 | 2011-02-09 | 에프. 호프만-라 로슈 아게 | P2x3 및 p2x2/3 조정자로서의 다이아미노피리미딘 |
| JP4850912B2 (ja) * | 2005-09-01 | 2012-01-11 | エフ.ホフマン−ラ ロシュ アーゲー | P2x3およびp3x2/3モジュレーターとしてのジアミノピリミジン |
| CN101300235B (zh) | 2005-09-01 | 2011-12-07 | 弗·哈夫曼-拉罗切有限公司 | 作为p2x3和p2x2/3调节剂的二氨基嘧啶类化合物 |
| JP4850911B2 (ja) * | 2005-09-01 | 2012-01-11 | エフ.ホフマン−ラ ロシュ アーゲー | P2x3およびp2x2/3モジュレーターとしてのジアミノピリミジン |
| RU2433119C2 (ru) * | 2006-04-28 | 2011-11-10 | Шионоги Энд Ко., Лтд. | Производное амина, обладающее антагонистической активностью в отношении рецептора npy y5 |
| ZA200809146B (en) * | 2006-04-28 | 2009-12-30 | Shionogi & Co | Amine derivative having NPY Y5 receptor antagonist activity |
| AU2007244358B2 (en) * | 2006-04-28 | 2012-06-14 | Shionogi & Co., Ltd. | Amine derivative having NPY Y5 receptor antagonist activity |
| SA08290668B1 (ar) | 2007-10-25 | 2012-02-12 | شيونوجي آند كو.، ليمتد | مشتقات أمين لها نشاط مضاد لمستقبل npy y5 واستخداماتها |
| US8227618B2 (en) | 2009-04-23 | 2012-07-24 | Shionogi & Co., Ltd. | Amine-derivatives having NPY Y5 receptor antagonistic activity and the uses thereof |
| EP2498782B1 (en) | 2009-11-12 | 2019-01-09 | Pharmatrophix Inc. | Crystalline forms of neurotrophin mimetic compounds and their salts |
| US10273219B2 (en) | 2009-11-12 | 2019-04-30 | Pharmatrophix, Inc. | Crystalline forms of neurotrophin mimetic compounds and their salts |
| EA027792B1 (ru) | 2011-04-08 | 2017-09-29 | Янссен Сайенсиз Айрлэнд Юси | Производные пиримидина для лечения вирусных инфекций |
| CN104066733A (zh) | 2011-11-09 | 2014-09-24 | 爱尔兰詹森研发公司 | 用于治疗病毒感染的嘌呤衍生物 |
| SG11201408542VA (en) | 2012-07-13 | 2015-02-27 | Janssen Sciences Ireland Uc | Macrocyclic purines for the treatment of viral infections |
| EP2882721B1 (en) * | 2012-08-10 | 2018-12-05 | Janssen Sciences Ireland Unlimited Company | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases |
| KR102280595B1 (ko) | 2012-10-10 | 2021-07-22 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 바이러스 감염 및 다른 질환 치료를 위한 피롤로[3,2-d]피리미딘 유도체 |
| CN105051018B (zh) | 2012-11-16 | 2019-09-20 | 爱尔兰詹森科学公司 | 用于治疗病毒性感染的杂环的经取代的2-氨基-喹唑啉衍生物 |
| CN105189468B (zh) | 2013-02-21 | 2018-10-30 | 爱尔兰詹森科学公司 | 用于治疗病毒性感染的2-氨基嘧啶衍生物 |
| BR112015022836A2 (pt) | 2013-03-15 | 2017-07-18 | Pharmatrophix Inc | miméticos de neurotrofina bdnf não peptídicos |
| AU2014227623B2 (en) | 2013-03-15 | 2018-08-16 | Pharmatrophix, Inc. | Non-peptide BDNF Neurotrophin mimetics |
| MX366481B (es) | 2013-03-29 | 2019-07-09 | Janssen Sciences Ireland Uc | Deaza-purinonas macrociclicas para el tratamiento de infecciones virales. |
| DK3004074T3 (da) | 2013-05-24 | 2018-01-29 | Janssen Sciences Ireland Uc | Pyridonderivater til behandling af virusinfektioner og yderligere sygdomme |
| NO3030563T3 (enExample) | 2013-06-27 | 2018-01-06 | ||
| MX368625B (es) | 2013-07-30 | 2019-10-08 | Janssen Sciences Ireland Uc | Derivados de tieno[3,2-d]pirimidinas para el tratamiento de infecciones virales. |
| CA3027471A1 (en) | 2016-07-01 | 2018-01-04 | Janssen Sciences Ireland Unlimited Company | Dihydropyranopyrimidines for the treatment of viral infections |
| CN109790154B (zh) | 2016-09-29 | 2023-06-23 | 爱尔兰詹森科学公司 | 用于治疗病毒感染和另外的疾病的嘧啶前药 |
| TW201945003A (zh) | 2018-03-01 | 2019-12-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 2,4-二胺基喹唑啉衍生物及其醫學用途 |
| WO2020045334A1 (ja) | 2018-08-27 | 2020-03-05 | 大日本住友製薬株式会社 | 光学活性なアザビシクロ環誘導体 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2691655A (en) | 1952-05-24 | 1954-10-12 | Burroughs Wellcome Co | 2-amino-4-substituted amino-6-aryl pyrimidines and process of preparing same |
| GB951432A (en) | 1959-03-17 | 1964-03-04 | Wellcome Found | Pyrimidine derivatives and the manufacture thereof |
| US3862190A (en) | 1972-09-08 | 1975-01-21 | Pfizer | 5-(unsubstituted and substituted phenoxy)-4-amino pyrimidines |
| DK397574A (enExample) * | 1973-08-24 | 1975-04-28 | Ciba Geigy Ag | |
| GB1523274A (en) | 1974-08-05 | 1978-08-31 | Ici Ltd | Herbicidal compositions containing substituted pyrimidine |
| FR2358148A1 (fr) | 1976-07-12 | 1978-02-10 | Dick Pr | Derives de 2,4-diaminopyrimidines et leur mise en solution en association avec des sulfamides |
| FR2397407A2 (fr) | 1977-07-11 | 1979-02-09 | Dick Pierre | Derives de 2,4-diamino pyrimidines et leur mise en solution en association avec des sulfamides |
| FI895821A7 (fi) | 1988-12-07 | 1990-06-08 | The Wellcome Foundation Ltd | Farmaseuttisesti aktivisia CNS-yhdisteitä |
| GB9012316D0 (en) | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
| IE912114A1 (en) | 1990-07-02 | 1992-01-15 | Union Pharma Scient Appl | Novel pyrimidine derivatives which are angiotensin ii¹receptor antagonists, their methods of preparation and¹pharmaceutical compositions in which they are present |
| US5075305A (en) | 1991-03-18 | 1991-12-24 | Warner-Lambert Company | Compound, composition and use |
| DE69201559T2 (de) | 1991-04-17 | 1995-07-13 | Pfizer | Pyrimidinderivate zur erhöhung der antitumoraktivität. |
| US5336677A (en) | 1991-10-24 | 1994-08-09 | American Home Products Corporation | Substituted aminopyrimidines as antihypertensives |
| GB9125842D0 (en) | 1991-12-04 | 1992-02-05 | Ici Plc | Heterocyclic derivatives |
| JPH08504798A (ja) | 1992-12-18 | 1996-05-21 | ザ ウエルカム ファウンデーション リミテッド | 酵素阻害薬としての,ピリミジン,ピリジン,プテリジノンおよびインダゾール誘導体 |
| DE69408750T2 (de) | 1993-08-26 | 1998-07-23 | Ono Pharmaceutical Co | 4-Aminopyrimidin Derivate |
| JPH08283246A (ja) | 1994-06-01 | 1996-10-29 | Nippon Soda Co Ltd | ピリミジン誘導体、その製造方法及び有害生物防除剤 |
| WO1996031488A1 (en) | 1995-04-03 | 1996-10-10 | Sumitomo Pharmaceuticals Company, Limited | Novel pyrimidine derivatives efficacious as psychotropic drug and process for the production thereof |
| US6440965B1 (en) | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
-
1999
- 1999-04-08 US US09/288,495 patent/US6583148B1/en not_active Expired - Fee Related
-
2000
- 2000-04-06 CA CA002368843A patent/CA2368843C/en not_active Expired - Fee Related
- 2000-04-06 AU AU43314/00A patent/AU4331400A/en not_active Abandoned
- 2000-04-06 WO PCT/US2000/009108 patent/WO2000061562A1/en not_active Ceased
- 2000-04-06 US US09/958,511 patent/US6916820B1/en not_active Expired - Fee Related
- 2000-04-06 DE DE60037013T patent/DE60037013T2/de not_active Expired - Lifetime
- 2000-04-06 AT AT00923138T patent/ATE377592T1/de not_active IP Right Cessation
- 2000-04-06 EP EP00923138A patent/EP1165523B1/en not_active Expired - Lifetime
- 2000-04-06 JP JP2000610837A patent/JP4743463B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP4743463B2 (ja) | 2011-08-10 |
| EP1165523A1 (en) | 2002-01-02 |
| WO2000061562A1 (en) | 2000-10-19 |
| JP2002541245A (ja) | 2002-12-03 |
| AU4331400A (en) | 2000-11-14 |
| DE60037013T2 (de) | 2008-08-21 |
| EP1165523B1 (en) | 2007-11-07 |
| US6583148B1 (en) | 2003-06-24 |
| CA2368843A1 (en) | 2000-10-19 |
| US6916820B1 (en) | 2005-07-12 |
| ATE377592T1 (de) | 2007-11-15 |
| DE60037013D1 (de) | 2007-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2368843C (en) | Neurotrophic substituted pyrimidines | |
| US6440965B1 (en) | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system | |
| CA2416442C (en) | Substituted 5-alkynyl pyrimidines having neurotrophic activity | |
| EP1165522A1 (en) | Neurotrophic thio substituted pyrimidines | |
| US5587380A (en) | Certain 2,4-diamino-5-(2,3,5-TRI-chlorophenyl)-6-substituted-pyrimidines which are pharmacologically active CNS compounds | |
| EP0257102B1 (en) | Agents for treating neurophathy | |
| US5589477A (en) | Pyrimidine derivatives and drugs | |
| SK278444B6 (en) | Substituted 5-arylpyrimidine, manufacturing process thereof and pharmaceutical composition containing its | |
| CA2499497A1 (en) | Substituted pyrimidines | |
| US4992444A (en) | Antifolate agents | |
| US5358945A (en) | Pyrimidine compound and pharmaceutically acceptable salts thereof | |
| US20080234301A1 (en) | Alpha-4 Integrin Mediated Cell Adhesion Inhibitors for the Treatment or Prevention of Inflammatory Diseases | |
| JPWO2000078730A1 (ja) | 新規ジヒドロピリミジン誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20140408 |